Revision as of 11:33, 31 December 2024 editIdoghor Melody (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, Page movers, IP block exemptions, New page reviewers, Pending changes reviewers33,933 editsm clean up, added orphan tagTag: AWB← Previous edit | Revision as of 00:51, 2 January 2025 edit undoGraeme Bartlett (talk | contribs)Administrators249,807 edits added Category:Diols using HotCatNext edit → | ||
Line 119: | Line 119: | ||
] | ] | ||
] | ] | ||
] | |||
Revision as of 00:51, 2 January 2025
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024) |
Pharmaceutical compound
Clinical data | |
---|---|
Other names | 2'-Deoxythioguanosine |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H13N5O3S |
Molar mass | 283.31 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Ateganosine is a telomerase inhibitor and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).
References
- Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, et al. (January 2024). "A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer". Nature Communications. 15 (1): 672. doi:10.1038/s41467-024-44861-8. PMC 10803750. PMID 38253555.
- "Ateganosine". PatSnap.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |